{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:51:23Z","timestamp":1790884283047,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.14283\/jpad.2022.21","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T05:37:14Z","timestamp":1643175434000},"page":"211-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy"],"prefix":"10.1016","volume":"9","author":[{"given":"Jerome","family":"Barakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Suhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chalkias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Burkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Marsica","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Castrillo-Viguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vijverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2022.21_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.21_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.14283\/jpad.2022.21_bib3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.14283\/jpad.2022.21_bib4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11481-016-9722-5","article-title":"Safety and efficacy of anti-amyloid-\u03b2 immunotherapy in Alzheimer's disease: a systematic review and meta-analysis","volume":"12","author":"Penninkilampi","year":"2017","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.14283\/jpad.2022.21_bib5","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer's disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.14283\/jpad.2022.21_bib6","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.21_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.14283\/jpad.2022.21_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.dadm.2016.02.004","article-title":"Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease","volume":"2","author":"Carlson","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.14283\/jpad.2022.21_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement (NY)"},{"key":"10.14283\/jpad.2022.21_bib10","first-page":"255","article-title":"Clinical development of aducanumab, an anti-A\u03b2 human monoclonal antibody being investigated for the treatment of early Alzheimer's disease","volume":"4","author":"Budd Haeberlein","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2022.21_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2022.21_bib12","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.21_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2022.21_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.21_bib15","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR imaging features of amyloid-related imaging abnormalities","volume":"34","author":"Barakos","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.14283\/jpad.2022.21_bib16","author":"U.S. Food & Drug Administration (FDA)"},{"key":"10.14283\/jpad.2022.21_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease \u2014 one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.14283\/jpad.2022.21_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"issue":"Suppl. 5","key":"10.14283\/jpad.2022.21_bib19","first-page":"S105","article-title":"Vascular alterations in PDAPP mice after anti-A\u03b2 immunotherapy: implications for amyloid-related imaging abnormalities","volume":"9","author":"Zago","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.21_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3233\/JAD-160023","article-title":"Monitoring blood-brain barrier integrity following amyloid-\u03b2 immunotherapy using gadolinium-enhanced MRI in a PDAPP mouse model","volume":"54","author":"Blockx","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.14283\/jpad.2022.21_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2022.21_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13195-016-0193-y","article-title":"Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies","volume":"8","author":"Ivanoiu","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2022.21_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.14283\/jpad.2022.21_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2022.21_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer's disease patients","volume":"57","author":"Ketter","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.14283\/jpad.2022.21_bib26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jalz.2011.05.2353","article-title":"Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab","volume":"7","author":"Carlson","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.21_bib27","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1212\/WNL.0b013e3181e396ea","article-title":"Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population","volume":"74","author":"Goos","year":"2010","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.21_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fneur.2019.00008","article-title":"Association between cortical superficial siderosis and dementia in patients with cognitive impairment: a meta-analysis","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Neurol"},{"key":"10.14283\/jpad.2022.21_bib29","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2022.21_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2022.21_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2022.21_bib32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.trci.2017.05.003","article-title":"Ponezumab in mild-to-moderate Alzheimer's disease: randomized phase II PET-PIB study","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.14283\/jpad.2022.21_bib33","first-page":"106","article-title":"Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis","volume":"87","author":"Arrighi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.14283\/jpad.2022.21_bib34","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3233\/JAD-180675","article-title":"Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies","volume":"66","author":"Brashear","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.14283\/jpad.2022.21_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2022.21_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fneur.2015.00207","article-title":"Anti-A\u03b2 autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy","volume":"6","author":"DiFrancesco","year":"2015","journal-title":"Front Neurol"},{"key":"10.14283\/jpad.2022.21_bib37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ana.23857","article-title":"Anti-amyloid \u03b2 autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies","volume":"73","author":"Piazza","year":"2013","journal-title":"Ann Neurol"},{"key":"10.14283\/jpad.2022.21_bib38","doi-asserted-by":"crossref","first-page":"e877","DOI":"10.1212\/WNL.0000000000005060","article-title":"Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab","volume":"90","author":"Liu","year":"2018","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.21_bib39","unstructured":"von Rosenstiel P, Chen T, O'Gorman J, Yee M, Castrillo-Viguera C, Chalkias S, et al. Cumulative aducanumab safety data from PRIME: a randomized, double-blind, placebo-controlled, phase 1b study. Poster presented at the 11th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting, Barcelona, Spain, October 24\u201327, 2018."},{"issue":"Suppl. 1","key":"10.14283\/jpad.2022.21_bib40","first-page":"S168","article-title":"Aducanumab 48-month analyses from PRIME, a phase 1b study in patients with early Alzheimer's disease","volume":"5","author":"von Rosenstiel","year":"2018","journal-title":"J Prev Alz Dis"},{"key":"10.14283\/jpad.2022.21_bib41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/STROKEAHA.110.607184","article-title":"Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study","volume":"42","author":"Poels","year":"2011","journal-title":"Stroke"},{"key":"10.14283\/jpad.2022.21_bib42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/RLI.0b013e3181814d28","article-title":"Three-dimensional fluid attenuated inversion recovery imaging with isotropic resolution and nonselective adiabatic inversion provides improved three-dimensional visualization and cerebrospinal fluid suppression compared to two-dimensional FLAIR at 3 tesla","volume":"43","author":"Chagla","year":"2008","journal-title":"Invest Radiol"},{"key":"10.14283\/jpad.2022.21_bib43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.neurad.2018.02.007","article-title":"Evaluation of prospective motion correction of high-resolution 3D-T2-FLAIR acquisitions in epilepsy patients","volume":"45","author":"Vos","year":"2018","journal-title":"J Neuroradiol"},{"key":"10.14283\/jpad.2022.21_bib44","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.14283\/jpad.2022.21_bib45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/197140091302600501","article-title":"Susceptibility-weighted angiography of intracranial blood products and calcifications compared to gradient echo sequence","volume":"26","author":"Docampo","year":"2013","journal-title":"Neuroradiol J"},{"key":"10.14283\/jpad.2022.21_bib46","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jon.12422","article-title":"Validation of an MRI rating scale for amyloid-related imaging abnormalities","volume":"27","author":"Bechten","year":"2017","journal-title":"J Neuroimaging"},{"key":"10.14283\/jpad.2022.21_bib47","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3174\/ajnr.A3475","article-title":"An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion","volume":"34","author":"Barkhof","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.14283\/jpad.2022.21_bib48","doi-asserted-by":"crossref","unstructured":"Bracoud L, Fiebach J, Purcell D, Gaensler E, Gass A, Lindan C, et al. Validation of a simple severity scale for assessing ARIA-E. Poster presented at the Alzheimer's Association International Conference (AAIC), London, UK, July 16\u201320, 2017.","DOI":"10.1016\/j.jalz.2017.06.2311"},{"key":"10.14283\/jpad.2022.21_bib49","doi-asserted-by":"crossref","unstructured":"Galvin JE, Cummings JL, Levitchi Benea M, de Moor C, Atri A, Porter VR, et al. ICARE AD-US: design of a prospective, single-arm, multicenter, noninterventional real-world study of aducanumab in the United States. Oral presentation at the Alzheimer's Association International Conference (AAIC), Denver, CO, USA, July 25\u201330, 2021.","DOI":"10.1002\/alz.057522"},{"issue":"Suppl. 2","key":"10.14283\/jpad.2022.21_bib50","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1017\/S1041610211000950","article-title":"The use of CT in dementia","volume":"23","author":"Pasi","year":"2011","journal-title":"Int Psychogeriatr"},{"key":"10.14283\/jpad.2022.21_bib52","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00415-016-8377-8","article-title":"Posterior reversible encephalopathy syndrome","volume":"264","author":"Fischer","year":"2017","journal-title":"J Neurol"},{"key":"10.14283\/jpad.2022.21_bib53","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000260066.98681.2e","article-title":"Course of cerebral amyloid angiopathy-related inflammation","volume":"68","author":"Kinnecom","year":"2007","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.21_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1742-2094-10-39","article-title":"Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation","volume":"10","author":"Kimura","year":"2013","journal-title":"J Neuroinflammation"},{"key":"10.14283\/jpad.2022.21_bib55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2017-317347","article-title":"Minimally symptomatic cerebral amyloid angiopathy-related inflammation: three descriptive case reports","volume":"90","author":"Banerjee","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.14283\/jpad.2022.21_bib56","first-page":"e12101","article-title":"Symptomatic amyloid-related imaging abnormalities in an APOE \u03b54\/\u03b54 patient treated with aducanumab","volume":"12","author":"VandeVrede","year":"2020","journal-title":"Alzheimers Dement (Amst)"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:11:55Z","timestamp":1737321115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724003339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2274580724003339"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2022.21","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2022.21","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}